Go Deep
Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,745 | -4.9 | 2.12 | 0.13 | 339.03 |
| Oct 2026 | 21,086 | -4.4 | 1.93 | 0.13 | 306.68 |
| Oct 2026 | 20,993 | -4.5 | 1.98 | 0.13 | 315.27 |
| Oct 2026 | 21,055 | -4.5 | 1.95 | 0.13 | 308.77 |
| Oct 2026 | 20,921 | -4.6 | 2.02 | 0.13 | 321.43 |
| Oct 2026 | 20,776 | -4.8 | 2.11 | 0.13 | 334.70 |
| Oct 2026 | 20,652 | -5.0 | 2.18 | 0.13 | 345.22 |
| Oct 2026 | 20,704 | -4.7 | 2.15 | 0.13 | 339.81 |
Prelude Therapeutics Incorporated Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 5,704,000.0 | 4,580,000.0 | 5,640,000.0 | 6,500,000.0 |
| Net Profit | -13,921,000.0 | -10,385,000.0 | -16,457,000.0 | -19,725,000.0 |
| EPS | -0.1 | -0.1 | — | -0.3 |
Prelude Therapeutics Incorporated Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 12,140,000.0 | 7,000,000.0 | 0.0 | 0.0 |
| Net Profit | -99,498,000.0 | -127,173,000.0 | -121,832,000.0 | -115,438,000.0 |
| EPS | -1.3 | -1.7 | -2.0 | -2.4 |
Prelude Therapeutics Incorporated Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 141,315,000.0 | 175,515,000.0 | 277,665,000.0 | 220,500,000.0 | — |
| Total Liabilities | 72,678,000.0 | 44,056,000.0 | 40,575,000.0 | 25,063,000.0 | — |
| Total Equity | 68,637,000.0 | 131,459,000.0 | 237,090,000.0 | 195,437,000.0 | — |
Owes vs Owns
Prelude Therapeutics Incorporated owed $0.29 for every $1 it owned in Jun 2026, up from $0.11 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.29× | 0.51× | 0.25× | 0.15× | 0.11× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Prelude Therapeutics Incorporated Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 73.0%Fixed assets (tangible) 22.8%Other assets 4.1%
How it's funded — Dec 2025
Short-term debt 1.9%Long-term debt 10.6%Payables 2.8%Other liabilities 36.0%Shareholders' equity 48.6%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 103.2 | 133.6 | 232.9 | 201.7 |
| Receivables | 0.0 | 0.0 | 0.0 | 0.0 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 32.3 | 35.5 | 37.7 | 6.7 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 5.8 | 6.4 | 7.0 | 12.1 |
| Liabilities & equity | ||||
| Short-term debt | 2.7 | 2.7 | 1.5 | 1.8 |
| Long-term debt | 15.0 | 15.3 | 15.4 | 0.0 |
| Payables | 4.0 | 7.7 | 4.6 | 6.8 |
| Other liabilities | 50.9 | 18.3 | 19.1 | 16.5 |
| Shareholders' equity | 68.6 | 131.5 | 237.1 | 195.4 |
| Net tangible assets | 68.6 | 131.5 | 237.1 | 195.4 |
Prelude Therapeutics Incorporated Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -56,302,000.0 | -102,888,000.0 | -107,063,000.0 | -83,729,000.0 | — |
| Investing Activities | 53,459,000.0 | 90,191,000.0 | -34,646,000.0 | 81,691,000.0 | — |
| Financing Activities | 24,816,000.0 | -120,000.0 | 136,395,000.0 | 815,000.0 | — |